drugset / Trial / NCT03598348

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

NCT03598348

Phase 3 Unknown 288 enrolled Huazhong University of Science and Technology
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after First-line XELOX/SOX chemotherapy for Patients with Advanced Gastric Cancer

Timeline

Start
2018-01-16
Primary completion
2020-01-16
Completion
2020-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Rivoceranib Small molecule 250 mg Oral

Indications